335 related articles for article (PubMed ID: 23173866)
41. [Campylobacter genes responsible for the development and determinant of clinical features of Guillain-Barré syndrome].
Yuki N
Nihon Rinsho; 2008 Jun; 66(6):1205-10. PubMed ID: 18540372
[TBL] [Abstract][Full Text] [Related]
42. Fisher syndrome associated with IgG anti-GQ1b antibody following infection by a specific serotype of Campylobacter jejuni.
Ohtsuka K; Nakamura Y; Hashimoto M; Tagawa Y; Takahashi M; Saito K; Yuki N
Ophthalmology; 1998 Jul; 105(7):1281-5. PubMed ID: 9663234
[TBL] [Abstract][Full Text] [Related]
43. Cross-reactive epitopes present in campylobacter jejuni serotypes isolated from enteritis patients.
Grozdanova A; Poceva-Panovska A; Brezovska K; Trajkovska-Dokic E; Dimovski A; Apostolski S; Suturkova Lj
Prilozi; 2011; 32(1):113-25. PubMed ID: 21822182
[TBL] [Abstract][Full Text] [Related]
44. A Guillain-Barré syndrome-associated SIGLEC10 rare variant impairs its recognition of gangliosides.
Alborzian Deh Sheikh A; Gomaa S; Li X; Routledge M; Saigoh K; Numoto N; Angata T; Hitomi Y; Takematsu H; Tsuiji M; Ito N; Kusunoki S; Tsubata T
J Autoimmun; 2021 Jan; 116():102571. PubMed ID: 33223341
[TBL] [Abstract][Full Text] [Related]
45. Brucella melitensis infection associated with Guillain-Barré syndrome through molecular mimicry of host structures.
Watanabe K; Kim S; Nishiguchi M; Suzuki H; Watarai M
FEMS Immunol Med Microbiol; 2005 Aug; 45(2):121-7. PubMed ID: 16051063
[TBL] [Abstract][Full Text] [Related]
46. Comparative genomic analysis of Campylobacter jejuni associated with Guillain-Barré and Miller Fisher syndromes: neuropathogenic and enteritis-associated isolates can share high levels of genomic similarity.
Taboada EN; van Belkum A; Yuki N; Acedillo RR; Godschalk PC; Koga M; Endtz HP; Gilbert M; Nash JH
BMC Genomics; 2007 Oct; 8():359. PubMed ID: 17919333
[TBL] [Abstract][Full Text] [Related]
47. Molecular characterization of Campylobacter jejuni from patients with Guillain-Barré and Miller Fisher syndromes.
Endtz HP; Ang CW; van Den Braak N; Duim B; Rigter A; Price LJ; Woodward DL; Rodgers FG; Johnson WM; Wagenaar JA; Jacobs BC; Verbrugh HA; van Belkum A
J Clin Microbiol; 2000 Jun; 38(6):2297-301. PubMed ID: 10834992
[TBL] [Abstract][Full Text] [Related]
48. Origin of ganglioside complex antibodies in Guillain-Barré syndrome.
Kuijf ML; Godschalk PC; Gilbert M; Endtz HP; Tio-Gillen AP; Ang CW; van Doorn PA; Jacobs BC
J Neuroimmunol; 2007 Aug; 188(1-2):69-73. PubMed ID: 17604126
[TBL] [Abstract][Full Text] [Related]
49. [Pathogenesis of Guillain-Barré syndrome and Fisher's syndrome: molecular mimicry between antecedent infectious agents and components of nerve tissues].
Yuki N
Rinsho Shinkeigaku; 1995 Dec; 35(12):1373-5. PubMed ID: 8752400
[TBL] [Abstract][Full Text] [Related]
50. Association of Anti-GT1a Antibodies with an Outbreak of Guillain-Barré Syndrome and Analysis of Ganglioside Mimicry in an Associated Campylobacter jejuni Strain.
Zhang M; Gilbert M; Yuki N; Cao F; Li J; Liu H; Li Q; Meng F; Zhang J
PLoS One; 2015; 10(7):e0131730. PubMed ID: 26197476
[TBL] [Abstract][Full Text] [Related]
51. Campylobacter sialyltransferase gene polymorphism directs clinical features of Guillain-Barré syndrome.
Yuki N
J Neurochem; 2007 Nov; 103 Suppl 1():150-8. PubMed ID: 17986150
[TBL] [Abstract][Full Text] [Related]
52. Miller Fisher syndrome: toward a more comprehensive understanding.
Li H; Yuan J
Chin Med J (Engl); 2001 Mar; 114(3):235-9. PubMed ID: 11780304
[TBL] [Abstract][Full Text] [Related]
53. Clinical presentation and outcome of Guillain-Barré and related syndromes in relation to anti-ganglioside antibodies.
Carpo M; Pedotti R; Allaria S; Lolli F; Matà S; Cavaletti G; Protti A; Pomati S; Scarlato G; Nobile-Orazio E
J Neurol Sci; 1999 Oct; 168(2):78-84. PubMed ID: 10526187
[TBL] [Abstract][Full Text] [Related]
54. Enhanced, sialoadhesin-dependent uptake of Guillain-Barre syndrome-associated Campylobacter jejuni strains by human macrophages.
Heikema AP; Koning RI; Duarte dos Santos Rico S; Rempel H; Jacobs BC; Endtz HP; van Wamel WJ; Samsom JN
Infect Immun; 2013 Jun; 81(6):2095-103. PubMed ID: 23529622
[TBL] [Abstract][Full Text] [Related]
55. Synthetic disialylgalactose immunoadsorbents deplete anti-GQ1b antibodies from autoimmune neuropathy sera.
Willison HJ; Townson K; Veitch J; Boffey J; Isaacs N; Andersen SM; Zhang P; Ling CC; Bundle DR
Brain; 2004 Mar; 127(Pt 3):680-91. PubMed ID: 14960498
[TBL] [Abstract][Full Text] [Related]
56. Comprehensive analysis of bacterial risk factors for the development of Guillain-Barre syndrome after Campylobacter jejuni enteritis.
Koga M; Gilbert M; Takahashi M; Li J; Koike S; Hirata K; Yuki N
J Infect Dis; 2006 Feb; 193(4):547-55. PubMed ID: 16425134
[TBL] [Abstract][Full Text] [Related]
57. Guillain-Barré syndrome and anti-ganglioside antibodies: a clinician-scientist's journey.
Yuki N
Proc Jpn Acad Ser B Phys Biol Sci; 2012; 88(7):299-326. PubMed ID: 22850724
[TBL] [Abstract][Full Text] [Related]
58. [Guillain-barré syndrome associated Campylobacter jejuni serotype Penner 2: a case report].
Watanabe M; Kinoshita I; Hujimoto M; Nakane S; Motomura M; Nakamura T; Kusunoki S; Takahashi M; Saitoh K
No To Shinkei; 2001 Aug; 53(8):759-62. PubMed ID: 11577419
[TBL] [Abstract][Full Text] [Related]
59. Anti-ganglioside antibodies in patients with Guillain Barré syndrome and other neurological disorders.
Vaishnavi C; Behura C; Prabhakar S; Sharma A; Kharbanda P
Indian J Med Microbiol; 2013; 31(2):177-9. PubMed ID: 23867676
[TBL] [Abstract][Full Text] [Related]
60. Characterization of the specific interaction between sialoadhesin and sialylated Campylobacter jejuni lipooligosaccharides.
Heikema AP; Bergman MP; Richards H; Crocker PR; Gilbert M; Samsom JN; van Wamel WJ; Endtz HP; van Belkum A
Infect Immun; 2010 Jul; 78(7):3237-46. PubMed ID: 20421384
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
